|
Data used to estimate vaccine effectiveness (1–3)
|
| 1. Vaccine effectiveness of PPSV–23 and PCV–13 in preventing IPD used in Smith et. al's study [25] (%) |
|
PPSV–23
|
PCV–13
|
|
|
years post
|
aged 65–79
|
aged 80 and over
|
aged 65 and over
|
|
|
vaccination
|
base-case
|
low
|
high
|
base-case
|
low
|
high
|
base-case
|
low
|
high
|
|
| 1 |
80.0 |
60.0 |
90.0 |
67.0 |
20.0 |
85.0 |
85.0 |
60.0 |
95.0 |
|
| 3 |
73.0 |
50.0 |
83.0 |
53.0 |
0 |
83.5 |
80.0 |
45.0 |
90.0 |
|
| 5 |
58.0 |
30.5 |
80.0 |
32.0 |
0 |
75.0 |
70.0 |
30.0 |
87.0 |
|
| 7 |
33.0 |
13.0 |
48.0 |
10.0 |
0 |
30.0 |
60.0 |
22.5 |
77.5 |
|
| 10 |
0 |
0 |
10.0 |
0 |
0 |
10.0 |
50.0 |
15.0 |
68.0 |
|
| 15 |
0 |
0 |
10.0 |
0 |
0 |
10.0 |
33.0 |
0 |
60.0 |
|
| 2. Vaccine effectiveness of PPSV–23 in preventing vaccine type IPD (in high income countries) (%) |
|
|
(based on Cochrane database of systemic review [30]) |
|
| 82 |
69 |
90 |
|
|
| 3. Vaccine effectiveness of PCV–13 in preventing IPD and non-bacteremic CAP based on CApiTA study [31]) (%) |
|
Reduced non-bacteremic vaccine type CAP |
45.0 |
|
|
Reduced vaccine-type IPD |
|
75.0 |
|
|
VE in preventing IPD used in current study (%) (Based on 1, 2, and 3) |
|
PPSV–23
|
PCV–13
|
|
years post
|
aged 65–79
|
aged 80 and over
|
aged 65–79
|
aged 80 and over
|
|
vaccination
|
base-case
|
low
|
high
|
base-case
|
low
|
high
|
base-case
|
low
|
high
|
base-case
|
low
|
high
|
| 1 |
82.0 |
69.0 |
90.0 |
68.7 |
23.0 |
85.0 |
75.0 |
52.9 |
83.8 |
62.8 |
17.6 |
79.2 |
| 3 |
74.8 |
57.5 |
83.0 |
54.3 |
0.0 |
83.5 |
70.6 |
39.7 |
79.4 |
51.2 |
13.2 |
75.0 |
| 5 |
59.5 |
35.1 |
80.0 |
32.8 |
0.0 |
75.0 |
61.8 |
26.5 |
76.8 |
34.1 |
8.8 |
72.5 |
| 7 |
33.8 |
15.0 |
48.0 |
10.3 |
0.0 |
30.0 |
52.9 |
19.9 |
68.4 |
16.0 |
6.6 |
64.6 |
| 10 |
0 |
0 |
10.0 |
0 |
0 |
10.0 |
44.1 |
13.2 |
60.0 |
0 |
0 |
56.7 |
| 15 |
0 |
0 |
10.0 |
0 |
0 |
10.0 |
29.1 |
0 |
52.9 |
0 |
0 |
50.0 |
|
VE in preventing non-invasive vaccine type CAP used in current study (%) (Based on 1, 2, and 3) |
|
PPSV–23
|
PCV–13
|
|
years post
|
aged 65–79
|
aged 80 and over
|
aged 65–79
|
aged 80 and over
|
|
vaccination
|
base-case
|
low
|
high
|
base-case
|
low
|
high
|
base-case
|
low
|
high
|
base-case
|
low
|
high
|
| 1 |
- |
- |
- |
- |
- |
- |
45.0 |
31.8 |
50.3 |
37.7 |
26.6 |
42.1 |
| 3 |
- |
- |
- |
- |
- |
- |
42.4 |
23.8 |
47.6 |
30.7 |
17.3 |
34.6 |
| 5 |
- |
- |
- |
- |
- |
- |
37.1 |
15.9 |
46.1 |
20.4 |
8.8 |
25.4 |
| 7 |
- |
- |
- |
- |
- |
- |
31.8 |
11.9 |
41.0 |
9.6 |
3.6 |
12.4 |
| 10 |
- |
- |
- |
- |
- |
- |
26.5 |
7.9 |
36.0 |
0 |
0 |
0 |
| 15 |
- |
- |
- |
- |
- |
- |
17.5 |
0 |
31.8 |
0 |
0 |
0 |
